Sangamo Therapeutics Inc SEC Filings

Sangamo Therapeutics disclosed that its Chief Financial Officer, Prathyusha Duraibabu, resigned effective October 1, 2025 and will transition to part-time employment to continue as the company’s principal financial officer. The Board appointed Nikunj Jain, Vice President, Finance and Corporate Controller since September 2021, to serve as Sangamo’s principal accounting officer effective October 1, 2025. Mr. Jain’s employment agreement provides a $347,548 annual base salary and a target annual cash bonus equal to 30% of base salary; he remains eligible for annual equity awards and severance benefits under the company plans. Ms. Duraibabu’s amended agreement is expected to provide a $145,188 base salary and a $160,000 cash retention bonus payable January 31, 2026, subject to continued employment.

Sangamo Therapeutics reported that its Chief Financial Officer, Prathyusha Duraibabu, notified the company on September 9, 2025 that she will resign effective October 1, 2025 to join a privately-held artificial intelligence company. The filing states her departure is not due to any disagreement over the company’s operations, financial statements, internal controls, auditors, policies, or practices. For business continuity, Ms. Duraibabu will move to part-time employment on the Transition Date and will continue to serve as the company’s principal financial officer and principal accounting officer on an interim basis until a successor is appointed. The company acknowledged her contributions, including work on strategic collaborations and investment allocations as Sangamo focuses on becoming a neurology-focused genomic medicines company.

Sangamo Therapeutics (SGMO) presented updated registrational Phase 1/2 STAAR study data for isaralgagene civaparvovec (ST-920) for Fabry disease at ICIEM2025. As of the April 10, 2025 cutoff, 33 patients (age 18–67) were dosed with a median follow-up of 24 months and all 32 remaining patients had achieved at least 52 weeks of follow-up. The FDA agreed that STAAR data will serve as the primary basis for Accelerated Approval using the 52-week eGFR slope across patients as an intermediate clinical endpoint. Observed mean annualized eGFR slopes at 52 weeks were positive: 1.965 mL/min/1.73m2/year (95% CI: -0.153, 4.083) and RIRS estimate 2.020 (95% CI: -0.055, 4.095). Sangamo is preparing a BLA under Accelerated Approval with potential submission as early as Q1 2026, subject to securing additional funding.

Sangamo Therapeutics (SGMO) director and President & CEO Sandy Macrae reported a Form 4 disclosing a tax-withholding disposition tied to RSU vesting. On 08/24/2025, 7,488 shares were surrendered for mandatory tax withholding at the issuer's closing price of $0.5863 per share. The filing reports 2,183,972 shares beneficially owned following the transaction. The disposition reflects vested restricted stock units from prior grants and is described as a required withholding action under the company’s 2018 Equity Incentive Plan rather than an open-market sale. The filing details remaining scheduled vesting for multiple RSU grants, with specific vesting installments through February 2026 and January 2026 and contingent on continuous service.

Gregory D. Davis, Head of Research & Technology and an officer of Sangamo Therapeutics, Inc. (SGMO), reported a deemed disposition of 723 shares of the issuer's common stock on 08/24/2025 under Form 4. The transaction code is F and was a mandatory tax-withholding surrender of shares underlying vested restricted stock units (RSUs) using the issuer's closing price on 08/22/2025 of $0.5863 per share; the withholding is treated as a disposition for reporting purposes and not an open-market sale. Following the transaction, the reporting person beneficially owns 201,222 shares. The filing discloses the schedule of remaining RSU vesting installments and notes vesting is subject to continuous service and potential acceleration per the 2018 Equity Incentive Plan.

Sangamo Therapeutics insider filing shows routine RSU vesting and tax-withholding disposition. On 08/24/2025 the reporting person, Scott B. Willoughby (SVP, Chief Legal Officer, Secretary and Director), had 1,434 shares disposed of at a price of $0.5863 per share to satisfy mandatory tax withholding related to RSUs that vested that day.

After the withholding disposition the reporting person beneficially owns 748,243 shares. The filing details scheduled vesting: 2,574 shares from a Feb 24, 2023 RSU grant (with remaining installments through Feb 24, 2026), 178,125 shares from a Jan 22, 2024 RSU grant vesting through Jan 22, 2026, and 120,000 shares from a Feb 25, 2025 RSU grant with one-quarter vesting on Feb 25, 2026 and the remainder in eight quarterly installments. All vesting is conditioned on Continuous Service and any applicable acceleration under the 2018 EIP.

Sangamo Therapeutics insider Prathyusha Duraibabu, SVP and Chief Financial Officer, reported a routine disposition on 08/24/2025 of 1,792 shares of common stock. The shares were surrendered to the company solely to satisfy mandatory tax withholding on RSUs using the closing price of $0.5863 per share on 08/22/2025. Following the transaction the reporting person beneficially owns 744,487 shares, which include multiple RSU grants that vest over time: installments from a 02/24/2023 grant, a 01/22/2024 grant, and a 02/25/2025 grant, each subject to continuous service and plan terms.

Sangamo Therapeutics insider Nathalie Dubois-Stringfellow reported a small disposition tied to RSU tax withholding and continues to hold a substantial equity stake. The Form 4 shows that on 08/24/2025 she surrendered 1,792 shares to the company for mandatory tax withholding at a price of $0.5863 per share related to vested restricted stock units under the 2018 Equity Incentive Plan.

After the withholding disposition, the reporting person beneficially owns 766,089 shares. The filing details the schedule of outstanding RSU grants and future vesting: remaining installments from a 2023 grant, a 2024 grant vesting through January 22, 2026, and a 2025 grant with a first vesting on February 25, 2026, all subject to continuous service and plan acceleration provisions.

Sangamo Therapeutics filed a Form S-8 to register an additional 14,000,000 shares of common stock to be issued pursuant to its Amended and Restated 2018 Equity Incentive Plan. The filing incorporates prior Form S-8 registrations for 19,131,725, 9,900,000, 7,900,000, 10,000,000 and 11,000,000 shares.

The submission relies on incorporation by reference to the company’s recent periodic reports and includes key exhibits such as the Amended Plan and legal opinions; corporate officers including the CEO and CFO signed the registration.